Elicio Therapeutics (ELTX) Equity Ratio (2020 - 2026)

Elicio Therapeutics has reported Equity Ratio for 7 years, with the latest figure at 0.06 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 120.04% year-over-year to 0.06; the trailing twelve-month figure through Mar 2026 stood at 0.06 (down 120.04% YoY), and the FY2025 full-year result was 0.06, up 115.76% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.06, down from 0.06 in the prior quarter.
• The five-year high for Equity Ratio was 0.63 in Q2 2023, with the low at 4.51 in Q4 2022.
• Historically, Equity Ratio has averaged 0.57 across 5 years, with a median of 0.06 in 2026.
• Annual changes were most pronounced in 2022 — Equity Ratio sank 483.58% — and 2025, when it surged 159.22%.
• Elicio Therapeutics' Equity Ratio stood at 4.51 in 2022, then soared by 109.3% to 0.42 in 2023, then tumbled by 195.82% to 0.4 in 2024, then jumped by 115.76% to 0.06 in 2025, then sank by 200.12% to 0.06 in 2026.
• The last three Equity Ratio figures came in at 0.06 (Q1 2026), 0.06 (Q4 2025), and 0.13 (Q3 2025), per Business Quant data.